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MaOBJECTIVES An assay for molecular imaging of myocardial CXCR4 expression was evaluated, in order to obtain
mechanistic insights noninvasively based on quantitative positron emission tomography (PET).
BACKGROUND The chemokine receptor CXCR4 has emerged as a therapeutic target after acute myocardial infarction
(AMI), because of its role in inﬂammatory and progenitor cell recruitment.
METHODS PET with the speciﬁc CXCR4 ligand, gallium-68 (68Ga)-pentixafor, was performed in mice (n ¼ 53) and
compared with ex vivo autoradiography, immunohistochemistry, and left ventricular ﬂow cytometry. In addition,
12 patients were imaged at 2 to 8 days after AMI.
RESULTS In mice, 68Ga-pentixafor identiﬁed regional CXCR4 upregulation in the infarct region, peaking at 3 days
(infarct/remote [I/R] ratio 1.5  0.2 at 3 days vs. 1.2  0.3 at 7 days; p ¼ 0.03), corresponding to a ﬂow cytometry-based
peak of CD45þ leukocytes and immunohistochemical detection of CD68þ macrophages and Ly6Gþ granulocytes.
Blockade with the CXCR4 antagonist AMD3100 abolished the signal. No speciﬁc uptake was found in sham-operated
or control animals. Long-term treatment with oral enalapril attenuated the CXCR4 signal (I/R 1.2  0.2 at 3 days and 1.0
 0.0.1 at 7 days; p ¼ 0.01 vs. untreated). Patients showed variable degrees of CXCR4 upregulation in the infarct region.
No single clinical parameter allowed for prediction of CXCR4 signal strength. At multivariate analysis, a combination
of infarct size and time after reperfusion predicted the CXCR4 infarct signal (rmultiple ¼ 0.73; p ¼ 0.03). Infarct signal in
the myocardium was paralleled by elevated pentixafor uptake in bone marrow (r ¼ 0.61; p ¼ 0.04), which highlighted
systemic interactions.
CONCLUSIONS Targeted PET imaging with 68Ga-pentixafor identiﬁes the global and regional CXCR4 expression
pattern in myocardium and systemic organs. CXCR4 upregulation after AMI coincides with inﬂammatory cell inﬁltration,
but shows interindividual variability in patients. This may have implications for the response to CXCR4- or other
inﬂammation-targeted therapy, and for subsequent ventricular remodeling. (J Am Coll Cardiol Img 2015;8:1417–26)
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ABBR EV I A T I ON S
AND ACRONYMS
ACE = angiotensin-converting
enzyme
AMI = acute myocardial
infarction
CMR = cardiac magnetic
resonance
18F-FDG = 18F-
ﬂuorodeoxyglucose
68Ga = gallium-68
I/R = infarct to remote ratio
LAD = left anterior descending
coronary artery
LGE = late gadolinium
enhancement
LV = left ventricular
LVEF = left ventricular ejection
fraction
PET = positron emission
tomography
SPECT = single-photon
emission computed
tomography
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1418Recently, the role of CXCR4 in cardiovas-
cular disease has been emphasized. Progres-
sive atherosclerosis and acute myocardial
infarction (AMI) are inﬂammatory conditions
in which CXCR4 and its cognate ligand
CXCL12 (also known as stromal cell-derived
factor-1) are thought to be involved in leuko-
cyte recruitment to the injured region (3).
Experimental studies suggest that continuous
blockade of CXCR4 with the small mole-
cule antagonist AMD3100 leads to reduced
cardiac function and impaired survival after
AMI (4). However, a single-time treatment
results in improved healing and functional
recovery (4,5). As a consequence, a clinical
trial has been initiated that evaluates tran-
sient CXCR4 blockade in patients after
reperfused AMI (6).SEE PAGE 1427The beneﬁt of a CXCR4-targeted inter-
vention (or any other intervention) directed
toward myocardial inﬂammation may vary,based on the individual CXCR4 expression level in
the target tissue and in the hematopoietic organs.
Accordingly, noninvasive molecular imaging of this
chemokine receptor may be of considerable value
after AMI. We sought to evaluate the feasibility in a
translational setting. For this purpose, we employed a
highly speciﬁc tracer, gallium-68 (68Ga) pentixafor,
which has recently been introduced for positron
emission tomography (PET) of CXCR4 in tumors and
lymphoproliferative disease (7,8).METHODS
PENTIXAFOR SYNTHESIS. 68Ga-Pentixafor was syn-
thesized as previously described (8,9), using an
automated module and CPCR4.2 provided by Scin-
tomics (Fürstenfeldbruck, Germany).
ANIMAL MODEL AND EXPERIMENTAL PROTOCOL. The
local state authority approved all animal procedures
(Niedersächsisches Landesamt für Verbraucherschutz
und Lebensmittelsicherheit). Animals were main-
tained in accordance with the guiding principles of
the American Physiological Society. Male C57Bl/6
mice (Charles River, 24  2 g) underwent left anterior
descending coronary artery ligation (n ¼ 40), sham
surgery (n ¼ 8), or no surgery (n ¼ 5). A subgroup
of infarct mice (n ¼ 18) was treated with the
angiotensin-converting enzyme (ACE) inhibitor ena-
lapril (20 mg/kg/day), administered orally as previ-
ously described (10), from 2 days before surgery until7 days after. A second subgroup (n ¼ 5) underwent
acute CXCR4 blockade with intravenous AMD3100 (50
mg in 100 ml) immediately before PET tracer injection.
SMALL ANIMAL POSITRON EMISSION TOMOGRAPHY.
Scans were performed at 3 and 7 days after surgery,
using an Inveon DPET (Siemens, Knoxville, Tennes-
see), as previously described (11). 68Ga-Pentixafor
(9.6  1.7 MBq) was administered as a 0.10- to
0.15-ml bolus via the tail vein. A 10-min static scan
was acquired at 50 min after injection. Then,
18F-ﬂuorodeoxyglucose (18F-FDG) (8.6  2.1 MBq)
was injected to localize the heart and infarct
territory. After 30 min under continued isoﬂurane, a
second 10-min static scan was performed. Image
reconstruction and analysis were performed as previ-
ously described (11). Mean percent injected dose per
gram values were calculated for infarct, remote
myocardium, spleen, and vertebral bone marrow.
EX VIVO VALIDATION. A subgroup of mice (n¼ 8) was
killed by cervical dislocation after PET for autoradi-
ography of cardiac sections.Masson trichrome staining
identiﬁed collagen. CD68 immunostaining identiﬁed
macrophages. Ly6G immunostaining identiﬁed pol-
ymorphonuclear leukocytes (granulocytes). In addi-
tional groups of sham-operated (n ¼ 5) and infarcted
mice (n ¼ 8 at 3 days, n ¼ 8 at 7 days ) with and without
enalapril treatment, CD45-expressing leukocytes in
the heart were identiﬁed using ﬂow cytometry as pre-
viously described (12).
PATIENTS. Twelve consecutive patients (4 women,
8 men; 62  11 years) underwent myocardial perfu-
sion single-photon emission computed tomography
(SPECT) and pentixafor PET within 5  2 days (range 2
to 8 days) after acute ST-segment elevation myocar-
dial infarction. Ten patients also underwent cardiac
magnetic resonance (CMR) within 1 day of PET. All
had been treated by percutaneous coronary inter-
vention and stenting within a median of 4 hours
(range 2 to 20) of symptom onset.
Noninvasive imaging was obtained for clinical
purposes, to determine successful reperfusion, ven-
tricular function, and inﬂammatory burden. Patients
gave written informed consent before imaging. 68Ga-
Pentixafor was used clinically according to x13.2b of
the German Pharmaceuticals Act. The local ethical
committee was informed of data analysis for the
purpose of this study and agreed to the project.
NONINVASIVE CLINICAL IMAGING. Electrocardio-
graphically gated perfusion SPECT was obtained at
rest using 357  35 MBq 99mtechnetium-sestamibi
(GE Discovery 530c, GE Healthcare, Waukesha, Wis-
consin). Static PET images were acquired for 20 min
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1419using a Biograph mCT 128 scanner (Siemens, Knox-
ville, Tennessee), starting at 60 min after injection of
68Ga-Pentixafor (92  24 MBq). CMR consisted
of cine images of left ventricular (LV) function,
T2-weighted images of edema and late gadolinium
enhancement (LE) images of infarct using a 1.5-T
scanner (Magnetom Avanto, Siemens). Infarct size
was determined using a 60% threshold of maximal
activity from perfusion SPECT polar maps. Left
ventricular ejection fraction (LVEF) was determined
from gated SPECT.
SPECT, PET, and CMR images were visually
analyzed using the American Heart Association 17-
segment model and a previously established scoring
system with a severity scale of 0 to 4 (13). For multi-
organ analysis of pentixafor PET, mean standardized
uptake values were obtained for infarcted and remote
myocardium, bone marrow of vertebral bodies, the
spleen, the liver, and the blood pool using spherical
volumes of interest.
STATISTICAL ANALYSIS. Statistical analysis was
carried out with Medcalc (Mariakerke, Belgium) and
Prism 6 (GraphPad, San Diego, California). All data are
shown as mean  SD. A p value <0.05 was considered
statistically signiﬁcant. In mice, Student’s paired t-
test was used to compare serial data within individual
animals, and the unpaired t-test was used to compare
data between treated and untreated groups. Multiple
groups were compared using Kruskal-Wallis test with
Dunn’s post hoc corrections. Pearson’s correlation
was used to describe the univariate relationship
between pairs of continuous variables. Multiple
regression was performed to identify determinants of
the myocardial pentixafor signal in patients. Due to
the lack of signiﬁcance for any variable at univariate
analysis, groups of 2, 3, or 4 of the most plausible
major clinical characteristics (infarct size determined
by perfusion defect score, LVEF, time of imaging
after infarct, and time between symptom onset and
reperfusion) were forced into least-squares multiple
regression models, and the signiﬁcance of each model
was tested by analysis of variance. For regional
analysis in patients, independence of segments was
assumed, and the Mann-Whitney U-Test or Kruskal-
Wallis test were used for comparison of different
subgroups of segments.
RESULTS
PENTIXAFOR PET IDENTIFIES THE TIME COURSE OF
REGIONAL MYOCARDIAL CXCR4 UPREGULATION
AFTER MYOCARDIAL INFARCTION IN MICE. Healthy
control and sham-operated mice displayed no appre-
ciable myocardial accumulation of 68Ga-pentixafor,with some liver accumulation at 50 to 60 min.
Accordingly, both groups were pooled together for
further analysis. In contrast, 3 days after myocardial
infarction, a distinctly elevated signal was apparent
in the infarcted apical anterolateral myocardial wall
(Figure 1). Infarct size was 35% to 48% based on
18F-FDG polar map analysis. The infarct to remote
ratio (I/R) for 68Ga-pentixafor was 1.5  0.2 (p < 0.001
vs. control mice) at 3 days and dropped signiﬁcantly
to 1.2  0.3 at 7 days (p ¼ 0.03 vs. 3 days). AMD3100
lowered 68Ga-pentixafor infarct uptake to values not
different from background (I/R 1.1  0.1, p ¼ 0.004 vs.
3 days unblocked), indicating signal speciﬁcity.
Ex vivo autoradiography conﬁrmed speciﬁc
68Ga-pentixafor binding in the infarct territory as
indicated by concomitant Masson trichrome staining.
AMD3100 abolished the signal (Figure 2). At 3 days
post-MI, the radioisotope signal corresponded to
increased CD68þ and Ly6Gþ immunostaining of
macrophages and granulocytes in the damaged region.
Flow cytometry identiﬁed a marked increase of CD45þ
leukocytes in the LV myocardium at 3 days compared
with the sham-operated control mice (16.1  6.1  105
vs. 0.5  0.1  105; p < 0.001), which was diminished
by 63% by 7 days post-MI (5.3  1.7  105 p ¼ 0.04
vs. 3 days), consistent with 68Ga-pentixafor signal
decline.
CXCR4 IMAGING SIGNAL CAN BE MODULATED BY
DRUG INTERVENTION IN MICE. ACE inhibition
lowers splenic leukocyte recruitment to the infarct
and enhances healing (10). This intervention showed
an effect on 68Ga-pentixafor imaging. Following
treatment, 68Ga-pentixafor uptake was reduced at 3
days (I/R 1.2  0.2, p ¼ 0.05 vs. untreated) (Figure 3).
This effect was still present at 7 days post-MI, when
the 68Ga-pentixafor signal was decreased by 38%
compared with untreated animals (p ¼ 0.04), with a
corresponding reduction of I/R (1.0  0.1, p ¼ 0.01).
Flow cytometry demonstrated a similar temporal
reduction in ventricular leukocyte content at 3 days
(22%; p ¼ 0.16) and 7 days post-MI (47%; p ¼ 0.04
vs. untreated). Enalapril treatment did not affect
heart rate compared with untreated mice after MI
(482  33 beats/min vs. 479  28 beats/min; p ¼ 0.90).
CXCR4-TARGETED IMAGING CAN BE TRANSLATED
TO PATIENTS AFTER AMI. SPECT-deﬁned infarct size
was 16 15% of the LV (range 1 to 43), and LVEF was 49
 13% (range 24 to 65). The summed rest perfusion
defect score (SRS) was 15  9. CMR consistently
showed impaired wall motion (summed wall motion
impairment score 17  10, range 2 to 34), late
enhancement (summed LE score 17 10, range 3 to 35),
and elevated T2 signal (summed edema score 18  13,
FIGURE 1 Molecular Imaging With the CXCR4-Binding Agent 68Ga-Pentixafor After Myocardial Infarction in Mice
(A) Representative gallium-68 (68Ga)-pentixafor positron emission tomography (PET) images, fused with concomitant 18F-ﬂuordeoxyglucose
(FDG) images, show elevated regional uptake in the hypometabolic infarct territory at 3 days after myocardial infarction (MI), which declines
after 7 days and can be blocked by AMD3100. (B) Quantitative analysis of mean percent injected dose per gram (%ID/g) (left) and infarct-to-
remote myocardial activity ratio (right). HLA ¼ horizontal long axis; SA ¼ short axis.
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microvascular obstruction was identiﬁed in 3 patients.
Global pentixafor uptake score varied among
patients (mean 10  9, range 0 to 25), but did not
correlate signiﬁcantly with SRS, LE, or edema
scores. Figure 4 shows representative patients with
high and low pentixafor uptake in the infarct re-
gion. At univariate analysis, the pentixafor uptake
score did not correlate with other single variables.
Multivariate analysis, however, revealed that a
regression model incorporating SRS as a measure of
infarct size (rpartial ¼ 0.7; p ¼ 0.01) and time of
imaging after reperfusion (rpartial ¼ 0.63; p ¼ 0.04)
best described pentixafor uptake score (rmultiple ¼
0.73; p ¼ 0.03).
Segments with elevated pentixafor uptake (n ¼
55 of 204) compared with segments without elevated
pentixafor uptake, had higher perfusion defectscore and wall motion impairment score (2.3  1.2 vs.
0.4  0.7 and 2.4  1.1 vs. 0.5  0.9; p < 0.001, respec-
tively), and higher LE and edema score (3.0 1.4 vs. 0.3
 1.0 and 3.0  1.11.3 vs. 0.5  1.2; p < 0.001, respec-
tively). Pentixafor uptake did not differ between seg-
ments with LE with or without microvascular
obstruction. Finally, pentixafor uptake was highest in
segments with LE and with edema, whereas it was
lower but still elevated in segments without LE
but with edema. Segments with LE but without
edema and segments without LE and without edema
had the lowest pentixafor uptake (Figure 5).
MYOCARDIAL CXCR4-UPREGULATION IS RELATED
TO SYSTEMIC CXCR4 BIODISTRIBUTION. Results in
multiple organs are highlighted in Figure 6. Uptake in
the infarct region showed a signiﬁcant correlation
with global pentixafor uptake score (r ¼ 0.66;
FIGURE 2 Ex Vivo Validation of 68Ga-Pentixafor Signal
(A) Autoradiography of representative short-axis sections at 3 days after MI, without (top) and with (bottom) blockade by co-injected
AMD3100, shows speciﬁc 68Ga-pentixafor accumulation in the blue-stained infarct territory as deﬁned by Masson trichrome stain (right).
(B) CD68 and Ly6G immunostaining (brown) demonstrates association of autoradiography signal with inﬁltration of macrophages and poly-
morphonuclear leukocytes at 3 days post-MI. (C) Flow cytometry identiﬁes increased number of CD45þ leukocytes in the left ventricle after MI.
Abbreviations as in Figure 1.
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1421p ¼ 0.02). It was signiﬁcantly higher than that in
the remote myocardium (2.2  0.7 vs. 1.3  0.4;
p ¼ 0.002), but both were not signiﬁcantly correlated
(r ¼ –0.42; p ¼ 0.18).
Uptake in bone marrow was elevated above blood
level (3.0  0.5 vs. 2.0  0.8; p ¼ 0.02) and correlated
with infarct uptake (r ¼ 0.61; p ¼ 0.04), but not with
the remote myocardium (r ¼ 0.28; p ¼ 0.4). Among all
organs, uptake was highest in the spleen (6.6  2.1;
p < 0.001 vs. all others). Splenic uptake showed a
nonsigniﬁcant trend toward correlation with infarct
uptake (r ¼ 0.46; p ¼ 0.13), and correlated signiﬁ-
cantly with uptake in the remote myocardium
(r ¼ 0.88; p < 0.001) and blood (r ¼ 0.84; p < 0.001).
DISCUSSION
This translational work establishes 68Ga-pentixafor as
a molecular imaging marker of CXCR4 expressionafter AMI. It also provides mechanistic insights:
under well-controlled conditions of a small animal
model, pentixafor speciﬁcally indicates elevated
CXCR4 expression in the acutely infarcted myocardial
region. The time course of the signal closely matches
the time course of overall myocardial leukocyte
inﬁltration; it can be blocked by the antagonist
AMD3100, and it is attenuated by ACE inhibitor
treatment, which has previously been shown to
reduce inﬂammatory monocyte recruitment and
thereby facilitates myocardial repair (10).
Pre-clinical data show a consistent strength and
time course of the pentixafor signal. The clinical
situation in patients after AMI is more heteroge-
neous, probably because of the more complex clinical
environment. Some patients showed strong CXCR4
upregulation, whereas others showed little or no
signal early after MI. No single clinical parameter
allowed for the prediction of the presence and
FIGURE 3 68Ga-Pentixafor Response to Anti-Inﬂammatory Therapy
(A) Representative 68Ga-pentixafor PET images, fused with concomitant FDG images, show attenuation of CXCR4 expression in the infarct
territory at 3 and 7 days after MI by treatment with the angiotensin-converting enzyme inhibitor enalapril. (B) Quantitative assessment of 68Ga-
pentixafor %ID/g and infarct to remote activity ratio. (C) Flow cytometry identiﬁes reduction of CD45þ leukocytes in the left ventricle after MI
following enalapril treatment. Abbreviations as in Figure 1.
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FIGURE 4 Targeted Imaging Identiﬁes Various Levels of CXCR4 Expression in Patients
After AMI
Tomographic images of perfusion and uptake of the CXCR4-ligand 68Ga-pentixafor in 2
representative cases with intermediate size infarcts. (A) Lateral wall perfusion defect
(summed rest score 17) with high corresponding pentixafor uptake in the defect region in a
patient studied at 4 days after reperfusion. (B) Anteroseptal wall perfusion defect (sum-
med rest score 16) with very low, almost absent pentixafor uptake in the defect region in a
patient studied at 7 days after reperfusion. Polarmaps display entire left ventricular
myocardial activity with the base in the periphery, the apex in the center, the anterior wall
on top, the inferior wall on bottom, the lateral wall on the right and the septum on the
left. VLA ¼ vertical long axis; other abbreviations as in Figure 1.
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1423magnitude of CXCR4 upregulation in the infarct re-
gion. On multivariate analysis, a combination of
infarct size and an earlier time of imaging after
infarction was associated with the CXCR4 signal
strength to a moderate degree. Speculatively, other
factors that may have contributed are differences in
the response to ACE inhibitors (all patients received
either an ACE inhibitor or angiotensin receptor
blocker), differences in CXCR4 activation and
expression level on inﬂammatory and resident cells,
or differences in the number of recruited inﬂamma-
tory cells. However, independent of the underlying
cause, this heterogeneity of CXCR4 upregulation may
have both prognostic and therapeutic implications.
Novel drug interventions directed against CXCR4
(3,5,6), or other new or existing drugs aimed at
modulating post-infarct inﬂammation (14) may not
be equally efﬁcacious in all subjects (15). Subjects
with strong CXCR4 upregulation may respond
differently than those with low or no upregulation,
and they may differ in remodeling and likelihood of
recovery. In this context, CXCR4-targeted imaging
may help in the selection of ideal candidates for
novel therapies. These are worthwhile hypotheses to
be tested in subsequent studies, considering that, for
example, a small molecule inhibitor of CXCR4 is
already being tested to support myocardial repair
in patients (6).
Because of the nature of noninvasive molecular
imaging with radiopharmaceuticals, the image is a
composite signal of all cells and cell types present in
the respective tissue region. Hence, no speciﬁc in-
formation about the cellular source of the signal can
be provided by the imaging test, but correlation with
ex vivo data in the pre-clinical setting provides
further insights. It is known that CXCR4, which plays
a key role in cell trafﬁcking, is strongly expressed by a
broad range of leukocytes, including monocytes,
granulocytes, T cells, B cells, and natural killer cells,
and by bone-marrow derived progenitor cells (16,17).
The strong pentixafor imaging signal from bone
marrow and the spleen is consistent with this notion.
Furthermore, the pentixafor signal was highest in
infarcted mice at a time when overall inﬂammatory
cell inﬁltration reached its peak (18). Autoradiog-
raphy showed that the tracer signal co-localized with
immunohistochemical detection of macrophages and
granulocytes. Accordingly, it is likely that a majority
of the pentixafor-derived CXCR4 signal in the infarct
region originates from recruited inﬂammatory cells.
However, cardiomyocytes, ﬁbroblasts, and endothe-
lial cells have also been shown to express CXCR4
(19,20), where it may contribute to cardioprotection,
angiogenesis, and progenitor cell recruitment (3). Ouranimal model of permanent coronary occlusion,
which results in damage of the majority of resident
cardiac cells in the infarct region, along with the
clinical observation of strongest CXCR4 expression in
segments with transmural gadolinium late enhance-
ment indicating nonviability, suggests that the
contribution of resident cardiomyocytes to the
imaging signal is low. Nevertheless, a small portion
of the signal may stem from residual resident cells
and add to the signal derived from recruited inﬂam-
matory cells.
68Ga-Pentixafor has recently been introduced as a
CXCR4-targeted imaging agent with high afﬁnity,
high in vivo stability, and high target speciﬁcity (8). It
has primarily been used for imaging in tumors and
lymphoproliferative disease (7,21), and its safety and
dosimetry for human use have been published (22).
Previous in vitro work (7) showed a high afﬁnity of
68Ga-pentixafor for human CXCR4 and absence of
cross reactivity with CXCR7. Afﬁnity for murine
CXCR4 was markedly lower, but uptake was still
speciﬁc, and reactivity with murine CXCR7 was ab-
sent (7). This proﬁle is favorable for clinical
FIGURE 5 Uptake of 68Ga-Pentixafor
Uptake of 68Ga-pentixafor indicating various levels of CXCR4 expression in myocardial segments with different patterns of myocardial injury
as deﬁned by presence (þ) or absence () of gadolinium-diethylenetriamine pentaacetic acid (DTPA) late enhancement (LE) or edema on
T2-sequences (T2) at cardiac magnetic resonance imaging. (A) Representative short-axis slices characterizing 4 different types of segments.
(B) Results of segmental pentixafor uptake score in respective segment types. *p < 0.05 versus remote; **p < 0.05 versus all others.
Abbreviations as in Figure 1.
FIGURE 6 Relationship of Quantitative Myocardial Uptake of 68Ga-Pentixafor With Uptake in Hematopoetic Organs
(A) Aided by three-dimensional maximum intensity projections (MIP) and PET/computed tomography (CT) fusion images, spherical volumes of
interest are positioned in the infarct and remote myocardium, blood pool (left atrium), spleen, liver, and vertebral bone marrow. (B) Rela-
tionship between standardized uptake values (SUV) in infarct region and bone marrow, and between remote myocardium and spleen (r and p
shown for all patients; without outlier, r ¼ 0.66, p ¼ 0.03). Abbreviations as in Figure 1.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: AMI elicits an
early inﬂammatory response in damaged myocardial tissue,
which determines subsequent wound healing. This inﬂammatory
response has emerged as a target for therapies to support the
repair process. The chemokine receptor CXCR4 is expressed on
inﬂammatory and progenitor cells, and has been explored as a
target for molecular intervention. Visualization of the local
myocardial CXCR4 expression may be useful to characterize the
inﬂammatory state after myocardial infarction. In the present
study, a novel imaging assay has been established in mice and
translated to humans. It identiﬁes regional myocardial CXCR4
upregulation, and shows interindividual variability in patients.
TRANSLATIONAL OUTLOOK: Following initial proof of
feasibility, further clinical studies may employ CXCR4-targeted
imaging to investigate if upregulation early after myocardial
infarction has implications for subsequent LV remodeling and
outcome. Also, the novel imaging assay may be used for candi-
date selection and effectiveness monitoring in trials using small
molecule CXCR4 antagonists.
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1425application, and it is consistent with our results. In
addition to lower tracer afﬁnity, the small size of the
target structure and the relatively high positron range
of 68Ga may further contribute to noise in mouse
images. Nevertheless, blocking studies with AMD3100
conﬁrmed speciﬁcity, suggesting that the in vivo
signal primarily includes CXCR4-positive cells.
Post-infarct inﬂammation has been a target of
several molecular imaging studies (14,15). Many of
those used FDG as a broadly clinically available
tracer, which identiﬁes increased metabolic activity
in inﬂammatory cells (13,23,24). To identify inﬂam-
matory activity, FDG requires a strategy to suppress
physiological myocardial glucose use, which may not
always be successful. In addition to its speciﬁcity for
CXCR4 as a key molecule involved in inﬂammation,
pentixafor offers the advantage that such a strategy is
not required because of its generally very low reten-
tion in healthy myocardium. Hence, the value of
CXCR4-targeted imaging may also be tested in other
cardiovascular inﬂammatory conditions, such as
endocarditis, myocarditis, or sarcoidosis (25,26).
CXCR4 may also be a suitable target for imaging of the
inﬂammatory component of the vulnerable athero-
sclerotic plaque (27). Finally, it should be noted that
pentixafor-based imaging of CXCR4 provides insights
into systemic networks of inﬂammation. Previous
work has established links between post-infarct
inﬂammation and atherosclerotic activity, the
spleen, and the bone marrow as sources of inﬂam-
matory cells (28,29). The observed correlations be-
tween myocardial, splenic, bone marrow, and blood
activity in our patient studies suggest interrelation
and networking between these organs that may be
studied in other pathologies and in response to
therapy in the future (15).
STUDY LIMITATIONS. The precise cell population
contributing to the in vivo 68Ga-pentixafor signal
cannot be identiﬁed in the present study. The serial
mouse imaging data in combination with ﬂow
cytometry and histology suggest that immune cells
are strongly associated with the PET signal and
represent its majority. However, additional contri-
butions from activated resident cells or platelet ag-
gregates, which also express CXCR4, cannot be ruled
out.
Enalapril treatment was chosen as an intervention
based on previous work supporting its inhibitory
effect on inﬂammatory cell recruitment (10). A
contribution of its known blood pressure–lowering
effects cannot be ruled out completely, but is
unlikely because imaging results were paralleled by
ex vivo measurements of inﬂammatory cell numbers,because the late acquisition time point after injection
limits the potential inﬂuence of hemodynamics, and
because the imaging result in patients did not corre-
late with blood pressure.
Finally, because of the ﬁrst-in-human concept of
our work, the sample size of our patient analysis was
small, and absence of signiﬁcance, especially in the
regression analyses, should be interpreted with
caution.
CONCLUSIONS
Noninvasive PET imaging with 68Ga-pentixafor
identiﬁes regional CXCR4 upregulation early after
MI, which matches the time course of inﬂammatory
cell inﬁltration in the infarct region. The imaging
assay is translatable to the clinical setting, where it
identiﬁes variability among patients. The present
work lays a foundation for further studies testing the
usefulness of targeted CXCR4 imaging to determine
outcome after AMI or to guide therapeutic in-
terventions aimed at improved myocardial repair
through modulation of CXCR4 or other inﬂammatory
pathways.
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APPENDIX The applied methods are
described in more detail in the online version of
this article.
